摘要
目的观察依达拉奉联合巴曲酶治疗急性期脑梗死的疗效。方法将82例急性期脑梗死患者随机分为联合治疗组49例,巴曲酶组33例。联合治疗组给予依达拉奉30 mg静脉滴注,每12 h 1次,连用10 d;同时在第1、3、5天静脉滴注巴曲酶,剂量分别是10、5、5 BU。巴曲酶组则单用巴曲酶,用法同联合治疗组。2组治疗前后均进行神经功能缺损程度评分(NDS)及凝血功能指标检查。结果治疗前与治疗后第3天比较2组NDS,差别无统计学意义(P>0.05);治疗后第7、15天,联合治疗组NDS显著低于巴曲酶组(P<0.05);治疗后第15天与治疗前比较,2组NDS均显著下降(P<0.01)。联合治疗组的疗效显著优于巴曲酶组(P<0.05)。2组纤维蛋白原含量治疗后与治疗前比较,均显著性下降(联合治疗组:t=19.246,P<0.001;巴曲酶组:t=12.748,P<0.001)。结论依达拉奉联合巴曲酶治疗急性期脑梗死效果显著,能显著改善神经功能。
Objective To observe the curative effects of edaravone combined atroxobin on treating acute cerebral infarction（ACI）.Methods Eighty-two cases with ACI were randomly divided into two groups.United treatment group（49 cases） was treated with edaravone 30 mg by intervenous drop infusion,one time 12 hours,for 10 days.Meanwhile,batroxobin was given on the 1st,3rd,5th day with the dose of 10,5 and 5 BU,respectively.Batroxobin group（33 cases） was treated with batroxobin only,usage was the same as united treatment group.Neurological deficit scores（NDS） and the index of blood coagulation were examined before and after treatment in both groups.Results There was no significant difference in NDS between two groups before treatment and on the 3rd day after treatment（P〉0.05）.On the 7th,15th day after treatment,the NDS of united treatment group was lower than batroxobin group（P〈0.05）.The NDS of two groups decreased on the 15th after treatment than that before treatment（P〈0.01）.The total effective rate of the united treatment group was significantly higher than that of the batroxobin group（P〈0.05）.Fib of the two groups before treatment was significantly less than that after treatment（the united treatment group：t=19.246,P0.001;the batroxobin group：t=12.748,P0.001）.Conclusion Edaravone combined batroxobin are significantly effective in the therapy on ACI and can significantly improve nerve function.
出处
《新乡医学院学报》
CAS
2011年第6期743-745,共3页
Journal of Xinxiang Medical University
关键词
依达拉奉
巴曲酶
脑梗死
edaravone
batroxobin
cerebral infarction
